Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Laura Dumitrescu, Athanasios Papathanasiou, Catalina Coclitu, Afagh Garjani, Nikos Evangelou, Cris S. Constantinescu, Bogdan Ovidiu Popescu & Radu Tanasescu. (2023) An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy 24:4, pages 495-509.
Read now
Read now
Katja Thomas, Undine Proschmann & Tjalf Ziemssen. (2017) Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Pharmacotherapy 18:15, pages 1649-1660.
Read now
Read now
Catalina Coclitu, Cris S. Constantinescu & Radu Tanasescu. (2016) The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics 16:12, pages 1341-1356.
Read now
Read now
Emanuele D’Amico, Carmela Leone, Cinzia Caserta & Francesco Patti. (2015) Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Review of Neurotherapeutics 15:7, pages 803-824.
Read now
Read now
Articles from other publishers (8)
Elissa M. Milford, Lara Meital, Anna Kuballa, Michael C. Reade & Fraser D. Russell. (2022) Fingolimod does not prevent syndecan-4 shedding from the endothelial glycocalyx in a cultured human umbilical vein endothelial cell model of vascular injury. Intensive Care Medicine Experimental 10:1.
Crossref
Crossref
Claudia Fracasso, Alice Passoni, Laura Brambilla, Renato Mantegazza, Silvia Rossi, Marco Gobbi & Jacopo Lucchetti. (2022) A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis. Applied Sciences 12:12, pages 6102.
Crossref
Crossref
Amnon A. Berger, Emily R. Sottosanti, Ariel Winnick, Jonathan Izygon, Kevin Berardino, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath & Ivan Urits. (2021) Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). Neurology International 13:2, pages 207-223.
Crossref
Crossref
Noelyn Anne Hung, Fernando Guillermo Costa, Cheung‐Tak Hung & Mónica Esther Rosenberg. (2020) Bioequivalence Study of 2 Capsule Formulations of Fingolimod 0.5 mg Assessing Both Parent Drug and Active Metabolite in New Zealand Healthy Subjects (Truncated Design). Clinical Pharmacology in Drug Development 9:5, pages 610-620.
Crossref
Crossref
Claudia Mara Ribeiro, Sayonara Rangel Oliveira, Daniela Frizon Alfieri, Tamires Flauzino, Damacio Ramón Kaimen-Maciel, Andréa Name Colado Simão, Michael Maes & Edna Maria Vissoci Reiche. (2019) Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis. Inflammation Research 68:12, pages 1049-1059.
Crossref
Crossref
Mehrdad Gholamzad, Masoumeh Ebtekar, Mehdi Shafiee Ardestani, Maryam Azimi, Zeinab Mahmodi, Mohammad Javad Mousavi & Saeed Aslani. (2018) A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflammation Research 68:1, pages 25-38.
Crossref
Crossref
Sophie Steeland, Sara Van Ryckeghem, Griet Van Imschoot, Riet De Rycke, Wendy Toussaint, Leen Vanhoutte, Christian Vanhove, Filip De Vos, Roosmarijn E. Vandenbroucke & Claude Libert. (2017) TNFR1 inhibition with a Nanobody protects against EAE development in mice. Scientific Reports 7:1.
Crossref
Crossref
Nicola De Stefano, Diego G. Silva & Michael H. Barnett. (2017) Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. CNS Drugs 31:4, pages 289-305.
Crossref
Crossref